

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated June 16, 2020 (the “**Prospectus**”) issued by Kangji Medical Holdings Limited (the “**Company**”).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any Shares or other securities of the Company. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, or to, or for the account or benefit of U.S. persons except in transactions exempt from or not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

In connection with the Global Offering, Goldman Sachs (Asia) L.L.C. as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, to the extent permitted by the applicable laws and regulatory requirements of Hong Kong or elsewhere, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at such price, in such amounts and in such manners as the Stabilizing Manager, its affiliates or any person acting for it, may determine and at a level higher than that which might otherwise prevail in an open market for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be conducted at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Any market purchases of the Shares will be effected in compliance with all applicable laws and regulatory requirements. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing actions cannot be taken to support the price of the Shares for longer than the stabilization period which will begin on the Listing Date and is expected to expire on Sunday, July 19, 2020, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the Shares and the price of the Shares could fall.



## **Kangji Medical Holdings Limited**

**康基医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

### **GLOBAL OFFERING**

|   |          |  |
|---|----------|--|
| <b>Number of Offer Shares under the Global Offering</b> | <b>:</b> | <b>225,397,500 Shares (subject to the Over-allotment Option)</b>   |
| <b>Number of Hong Kong Offer Shares</b>                 | <b>:</b> | <b>22,540,000 Shares (subject to adjustment)</b>   |
| <b>Number of International Offer Shares</b>             | <b>:</b> | <b>202,857,500 Shares (subject to adjustment and the Over-allotment Option)</b>  |
| <b>Maximum Offer Price</b>                              | <b>:</b> | <b>HK\$13.88 per Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong Dollars and subject to refund)</b> |
| <b>Par Value</b>  | <b>:</b> | <b>US\$0.00001 per Share</b>   |
| <b>Stock Code</b>                                       | <b>:</b> | <b>9997</b>  |

*Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*

**Goldman  
Sachs**



**BofA SECURITIES** 

The Company has applied to the Listing Committee for the listing of, and permission to deal in, the Shares (i) in issue; (ii) to be issued under the Capitalization Issue; (iii) to be issued upon conversion of the Preferred Shares; (iv) to be issued pursuant to the Global Offering (including any Shares which may be sold pursuant to the exercise of the Over-allotment Option); and (v) which may be issued upon exercise of any share option granted under the Pre-IPO Share Option Plan. Assuming the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Monday, June 29, 2020, dealing in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. in Hong Kong on Monday, June 29, 2020. In the event the Over-allotment Option is exercised, an announcement will be made by the Company which will be posted on the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and on the website of the Company ([www.kangjimedical.com](http://www.kangjimedical.com)).

The Global Offering comprises the Hong Kong Public Offering of initially 22,540,000 Shares representing approximately 10% of the total number of Offer Shares initially available under the Global Offering, and the International Offering of initially 202,857,500 Shares (subject to adjustment and the Over-allotment Option) representing approximately 90% of the total number of Offer Shares initially available under the Global Offering. The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering – Allocation – Reallocation” in the Prospectus. In particular, Offer Shares may be reallocated from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares that may be reallocated to the Hong Kong Public Offering shall be 22,540,000 Offer Shares so that the total number of the Offer Shares available under the Hong Kong Public Offering will be 45,080,000 Offer Shares (representing double of the initial allocation to the Hong Kong Public Offering and 20% of the total number of Offer Shares initially available under the Global Offering), and the final Offer Price shall be fixed at the bottom-end of the indicative Offer Price range (i.e. HK\$12.36 per Offer Share) stated in the Prospectus.

In connection with the Global Offering, the Selling Shareholder is expected to grant the Over-allotment Option to the International Underwriters, exercisable at the discretion of the Joint Global Coordinators (for themselves and on behalf of the International Underwriters) within 30 days from the last day for lodging applications under the Hong Kong Public Offering (the last day for exercise of the Over-allotment Option being Sunday, July 19, 2020), to require the Selling Shareholder to sell up to an aggregate of 33,809,500 additional Shares, representing approximately 15% of the total number of Offer Shares initially being offered under the Global Offering, at the Offer Price under the International Offering, to solely cover the over-allocations in the International Offering, if any.

Subject to the granting of the approval for listing of, and permission to deal in, the Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Stock Exchange or on any other date as may be determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second business day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

The Offer Price will not be more than HK\$13.88 per Offer Share and is currently expected to be not less than HK\$12.36 per Offer Share, unless otherwise announced as further explained in the section headed “Structure of the Global Offering” in the Prospectus. Applicants for the Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK\$13.88 per Offer Share together with brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$13.88 per Offer Share.

**Applications for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the relevant Application Forms and the designated website ([www.eipo.com.hk](http://www.eipo.com.hk)) for White Form eIPO.**

Applicants who wish to be issued the Hong Kong Offer Shares in their own names should either (i) complete and sign the **WHITE** Application Form; or (ii) submit applications online through the designated website of the **White Form eIPO** Service Provider at [www.eipo.com.hk](http://www.eipo.com.hk) under the **White Form eIPO** service. Applicants who wish to have the Hong Kong Offer Shares issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants should either (i) complete and sign the **YELLOW** Application Form; or (ii) give **electronic application instructions** to HKSCC via CCASS.

Printed copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Tuesday, June 16, 2020 till 12:00 noon on Friday, June 19, 2020 (or such later date as may apply as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus) at:

- the following addresses of the Hong Kong Underwriters:

**Goldman Sachs (Asia) L.L.C.** 68/F, Cheung Kong Center  
2 Queen’s Road Central  
Hong Kong

**CLSA Limited** 18/F, One Pacific Place  
88 Queensway  
Hong Kong

**Merrill Lynch (Asia Pacific) Limited** 55/F, Cheung Kong Center  
2 Queen’s Road Central  
Hong Kong

- any of the following branches of the receiving bank for the Hong Kong Public Offering:

**Bank of China (Hong Kong) Limited**

|                         | <b>Branch Name</b>   | <b>Address</b>                                 |
|-------------------------|----------------------|--|
| <b>Hong Kong Island</b> | Gilman Street Branch | 136 Des Voeux Road Central, Hong Kong          |
| <b>Kowloon</b>          | Hoi Yuen Road Branch | 55 Hoi Yuen Road, Kwun Tong, Kowloon           |
|                         | Tsim Sha Tsui Branch | 24-28 Carnarvon Road, Tsim Sha Tsui, Kowloon   |
| <b>New Territories</b>  | Kau Yuk Road Branch  | 18-24 Kau Yuk Road, Yuen Long, New Territories |

Printed copies of the Prospectus, together with the **YELLOW** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Tuesday, June 16, 2020 till 12:00 noon on Friday, June 19, 2020 from the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or your stockbroker, who may have **YELLOW** Application Forms and printed copies of the Prospectus available.

The application for the Hong Kong Offer Shares will commence on Tuesday, June 16, 2020 through Friday, June 19, 2020. The application monies (including brokerage, SFC transaction levy and Stock Exchange trading fee) will be held by the receiving banks on behalf of the Company after the closing of the application lists and the refund monies, if any, will be returned to the applicant(s) without interest on or before Friday, June 26, 2020. Investors should be aware that the dealings in the Shares on the Stock Exchange are expected to commence on Monday, June 29, 2020.

The **WHITE** or **YELLOW** Application Form completed in accordance with the instructions printed thereon, together with a cheque or a banker's cashier order payable to "**BANK OF CHINA (HONG KONG) NOMINEES LIMITED – KANGJI MEDICAL PUBLIC OFFER**" attached should be deposited in the special collection boxes provided at any of the designated branches of the receiving bank referred to above and at the following times:

**Tuesday, June 16, 2020 – 9:00 a.m. to 5:00 p.m.**  
**Wednesday, June 17, 2020 – 9:00 a.m. to 5:00 p.m.**  
**Thursday, June 18, 2020 – 9:00 a.m. to 5:00 p.m.**  
**Friday, June 19, 2020 – 9:00 a.m. to 12:00 noon**

The latest time for lodging your application is 12:00 noon on Friday, June 19, 2020. The application lists will be open from 11:45 a.m. to 12:00 noon on that day, subject only to the weather conditions, as described in the section headed "How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus.

Applicants may apply online through the **White Form eIPO** service by submitting an application through the designated website at [www.eipo.com.hk](http://www.eipo.com.hk) (24 hours daily, except on the last day for applications) from 9:00 a.m. on Tuesday, June 16, 2020 till 11:30 a.m. on Friday, June 19, 2020 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Friday, June 19, 2020 or such later date as described in the section headed "How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus.

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates<sup>(1)</sup>:

**Tuesday, June 16, 2020 – 9:00 a.m. to 8:30 p.m.**  
**Wednesday, June 17, 2020 – 8:00 a.m. to 8:30 p.m.**  
**Thursday, June 18, 2020 – 8:00 a.m. to 8:30 p.m.**  
**Friday, June 19, 2020 – 8:00 a.m. to 12:00 noon**

*Note:*

(1) These times are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants and/or CCASS Investor Participants.

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Tuesday, June 16, 2020 until 12:00 noon on Friday, June 19, 2020 (24 hours daily, except on Friday, June 19, 2020, the last day for applications).

The latest time for inputting your **electronic application instructions** will be 12:00 noon on Friday, June 19, 2020, the last day for applications or such later time as described in the section headed "How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus.

If you are not a CCASS Investor Participant, you may instruct your broker or custodian who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf.

You will be deemed to have authorised HKSCC and/or HKSCC Nominees to transfer the details of your application to the Company, the Joint Global Coordinators and the Hong Kong Share Registrar.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to publish the announcement on the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on or before Friday, June 26, 2020 in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese) and on the Company’s website at [www.kangjimedical.com](http://www.kangjimedical.com) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk). The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be available at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares – 11. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the Offer Price as finally determined is less than the maximum Offer Price of HK\$13.88 per Offer Share (excluding brokerage, SFC transaction levy and the Stock Exchange trading fee payable thereon), or if the conditions of the Hong Kong Public Offering are not fulfilled in accordance with the section headed “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy and the Stock Exchange trading fee, will be refunded, without interest or the cheque or banker’s cashier order will not be cleared.

No temporary documents of title will be issued in respect of the Shares and no receipt will be issued for sums paid on application. Share certificates will only become valid documents of title when the Global Offering has become unconditional in all respects and none of the Underwriting Agreements has been terminated in accordance with its terms prior to 8:00 a.m. (Hong Kong time) on the Listing Date, i.e. Monday, June 29, 2020.

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. on Monday, June 29, 2020 (Hong Kong time), dealing in the Shares are expected to commence at 9:00 a.m. on Monday, June 29, 2020 (Hong Kong time). The Shares will be traded in board lots of 500 Shares each. The stock code of the Shares is 9997.

By order of the Board  
**KANGJI MEDICAL HOLDINGS LIMITED**  
**ZHONG Ming**  
*Chairman*

Hong Kong, June 16, 2020

*As at the date of this announcement, the board of Directors of the Company comprises Mr. ZHONG Ming and Ms. SHENTU Yinguang as executive Directors; Ms. CAI Li and Mr. CHEN Gang as non-executive Directors; and Mr. JIANG Feng, Mr. GUO Jian and Mr. CHEN Weibo as independent non-executive Directors.*